Arcus Biosciences, Inc. Payments to Acquire Marketable Securities
Arcus Biosciences, Inc. (RCUS) reported Payments to Acquire Marketable Securities of $332.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-05
- Arcus Biosciences, Inc. payments to acquire marketable securities for the quarter ending 2026-06-30 was $182.00M, a 13.04% increase year-over-year.
- Arcus Biosciences, Inc. payments to acquire marketable securities for the quarter ending 2026-03-31 was $150.00M, a 57.51% decline year-over-year.
- Arcus Biosciences, Inc. payments to acquire marketable securities for the quarter ending 2025-12-31 was $397.00M, a 130.81% increase year-over-year.
- Arcus Biosciences, Inc. payments to acquire marketable securities for the quarter ending 2025-09-30 was $165.00M, a 40.65% decline year-over-year.
- Arcus Biosciences, Inc. payments to acquire marketable securities for fiscal 2025 was $1.08B, a 3.16% increase from fiscal 2024.
- Arcus Biosciences, Inc. payments to acquire marketable securities for fiscal 2024 was $1.04B, a 32.36% increase from fiscal 2023.
- Arcus Biosciences, Inc. payments to acquire marketable securities for fiscal 2023 was $788.00M, a 36.50% decline from fiscal 2022.
- Arcus Biosciences, Inc. payments to acquire marketable securities for fiscal 2022 was $1.24B, a 72.60% increase from fiscal 2021.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $182.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $332.00M 10-Q · filed 2026-08-05 | $729.00M derived: sum of 3 quarters · filed 2026-08-05 | $894.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $150.00M 10-Q · filed 2026-05-05 | $547.00M derived: sum of 2 quarters · filed 2026-05-05 | $712.00M derived: sum of 3 quarters · filed 2026-05-05 | $873.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $397.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $562.00M derived: sum of 2 quarters · filed 2026-02-25 | $723.00M derived: sum of 3 quarters · filed 2026-08-05 | $1.08B 10-K · filed 2026-02-25 |
| 2025-09-30 | $165.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $326.00M derived: sum of 2 quarters · filed 2026-08-05 | $679.00M 10-Q · filed 2025-10-28 | $851.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $161.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $514.00M 10-Q · filed 2026-08-05 | $686.00M derived: sum of 3 quarters · filed 2026-08-05 | $964.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $353.00M 10-Q · filed 2026-05-05 | $525.00M derived: sum of 2 quarters · filed 2026-05-05 | $803.00M derived: sum of 3 quarters · filed 2026-05-05 | $1.01B derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $172.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $450.00M derived: sum of 2 quarters · filed 2026-02-25 | $656.00M derived: sum of 3 quarters · filed 2026-02-25 | $1.04B 10-K · filed 2026-02-25 |
| 2024-09-30 | $278.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $484.00M derived: sum of 2 quarters · filed 2025-10-28 | $871.00M 10-Q · filed 2025-10-28 | $986.00M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $206.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $593.00M 10-Q · filed 2025-08-06 | $708.00M derived: sum of 3 quarters · filed 2026-02-25 | $988.00M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $387.00M 10-Q · filed 2025-05-06 | $502.00M derived: sum of 2 quarters · filed 2026-02-25 | $782.00M derived: sum of 3 quarters · filed 2026-02-25 | $1.02B derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $115.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $395.00M derived: sum of 2 quarters · filed 2026-02-25 | $634.00M derived: sum of 3 quarters · filed 2026-02-25 | $788.00M 10-K · filed 2026-02-25 |
| 2023-09-30 | $280.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $519.00M derived: sum of 2 quarters · filed 2024-11-06 | $673.00M 10-Q · filed 2024-11-06 | $829.00M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $239.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $393.00M 10-Q · filed 2024-08-08 | $549.00M derived: sum of 3 quarters · filed 2025-02-25 | $871.00M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $154.00M 10-Q · filed 2024-05-08 | $310.00M derived: sum of 2 quarters · filed 2025-02-25 | $632.00M derived: sum of 3 quarters · filed 2025-02-25 | $1.02B derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $156.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $478.00M derived: sum of 2 quarters · filed 2025-02-25 | $864.00M derived: sum of 3 quarters · filed 2025-02-25 | $1.24B 10-K · filed 2025-02-25 |
| 2022-09-30 | $322.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $708.00M derived: sum of 2 quarters · filed 2023-11-07 | $1.08B 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $386.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $763.00M 10-Q · filed 2023-08-07 | ||
| 2022-03-31 | $377.00M 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $719.00M 10-K · filed 2024-02-21 | |||
| 2020-12-31 | $740.00M 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |